A complex variant t(3;15) (q26;q13) representing cryptic/masked acute promyelocytic leukaemia with a novel breakpoint of chromosome 15—a case report

Acute promyelocytic leukaemia (APML) is a biologically and clinically distinct variant of AML, currently classified as acute myeloid leukaemia with recurrent cytogenetic anomalies t(15;17) (q22;q21), promyelocytic leukaemia-retinoic acid receptor alpha, diagnosis regardless of blast count in the Wor...

Descripción completa

Detalles Bibliográficos
Autores principales: Appachu, Sandhya, Obulareddy, Chintaparthi, Sirsath, Nagesh T, Lakshmaiah, Kuntejowdahalli C, Kumari, Prasanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757957/
https://www.ncbi.nlm.nih.gov/pubmed/24009642
http://dx.doi.org/10.3332/ecancer.2013.340
Descripción
Sumario:Acute promyelocytic leukaemia (APML) is a biologically and clinically distinct variant of AML, currently classified as acute myeloid leukaemia with recurrent cytogenetic anomalies t(15;17) (q22;q21), promyelocytic leukaemia-retinoic acid receptor alpha, diagnosis regardless of blast count in the World Health Organization classification system. It is one of the curable malignancies, has a unique clinical presentation, often with disseminated intravascular coagulation, and has a targeted therapy for its treatment in the form of all trans retinoic acid (ATRA) and arsenic trioxide (ATO). Here, we report a complex type of variant APML t(3;15) (q26;q13), the need for conventional karyotyping for diagnosing such rare variants, and its response to ATRA and ATO.

Ejemplares similares